Vir Biotechnology, Inc. Lease, Cost
Vir Biotechnology, Inc. (VIR) reported Lease, Cost of $18.45 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:LeaseCost · last filed 2026-02-23
- Vir Biotechnology, Inc. lease, cost for the quarter ending 2020-12-31 was $1.78M.
- Vir Biotechnology, Inc. lease, cost for the quarter ending 2020-09-30 was $1.73M.
- Vir Biotechnology, Inc. lease, cost for the quarter ending 2020-06-30 was $1.95M.
- Vir Biotechnology, Inc. lease, cost for the quarter ending 2020-03-31 was $1.89M.
- Vir Biotechnology, Inc. lease, cost for fiscal 2025 was $18.45M, a 15.18% decline from fiscal 2024.
- Vir Biotechnology, Inc. lease, cost for fiscal 2024 was $21.75M, a 12.75% decline from fiscal 2023.
- Vir Biotechnology, Inc. lease, cost for fiscal 2023 was $24.93M, a 4.43% decline from fiscal 2022.
- Vir Biotechnology, Inc. lease, cost for fiscal 2022 was $26.09M, a 58.69% increase from fiscal 2021.
| Period end | Lease, Cost 3 month | Lease, Cost 6 month | Lease, Cost 9 month | Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $18.45M 10-K · filed 2026-02-23 | |||
| 2024-12-31 | $21.75M 10-K · filed 2026-02-23 | |||
| 2023-12-31 | $24.93M 10-K · filed 2026-02-23 | |||
| 2022-12-31 | $26.09M 10-K · filed 2025-02-27 | |||
| 2021-12-31 | $16.44M 10-K · filed 2024-02-26 | |||
| 2020-12-31 | $1.78M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $3.51M derived: sum of 2 quarters · filed 2023-02-28 | $5.46M derived: sum of 3 quarters · filed 2023-02-28 | $7.35M 10-K · filed 2023-02-28 |
| 2020-09-30 | $1.73M 10-Q · filed 2020-11-10 | $3.68M derived: sum of 2 quarters · filed 2020-11-10 | $5.57M 10-Q · filed 2020-11-10 | |
| 2020-06-30 | $1.95M 10-Q · filed 2020-08-11 | $3.84M 10-Q · filed 2020-08-11 | ||
| 2020-03-31 | $1.89M 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |